Class / Patent application number | Description | Number of patent applications / Date published |
424900800 | Diagnostic or test agent produces visible change on skin | 42 |
20080299045 | Composition for Prevention, Treatment, and Diagnosis of Chronic Obstructive Pulmonary Disease (Copd) - The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein. | 12-04-2008 |
20090110641 | METHOD AND APPARATUS FOR NON-INVASIVE MEASUREMENT OF SKIN TISSUE CHOLESTEROL - The present invention provides a method and apparatus for non-invasive measurement of skin cholesterol. More particularly, one aspect of the invention provides for a device to apply a detector reagent to a selected area of skin. Another an indicator device to produce a visual change corresponding to the amount of detector reagent that is bound in the skin. The method and apparatus of this invention typically do not require any instrumentation for certain embodiments, allowing the invention to be suitable for self-testing, for example, but not limited to, in the home environment. As such the invention is particularly useful to allow individuals to assess their risk of atherosclerosis and related vascular diseases. | 04-30-2009 |
20090142275 | Wound Suture Capable of Identifying the Presence of Bacteria - A wound suture containing a solvatochromatic indicator that undergoes a color change in the presence of bacteria often associated with surgical site infection is provided. Such a color change provides a “real time” indication of the onset of infection, which may alert medical staff to apply an appropriate antimicrobial treatment (e.g., antibiotic) to the patient (e.g., human or animal) before a more serious infection occurs. The patient may also be able to accurately monitor the condition of a wound after discharge from the hospital. Further, the lack of a color change may provide the medical staff or patient with the assurance that the area is generally free of infection and clean. | 06-04-2009 |
20090280065 | Uses and Compositions for Treatment of Psoriasis - The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject. | 11-12-2009 |
20100272652 | DETERMINATION OF TRACERS WITHIN SUBJECTS - The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When administered to a subject (e.g., ingested), the tracer and the substance to be administered may be absorbed and/or metabolized by the subject, and the pharmacokinetic activity of the tracer within the subject may be related to the pharmacokinetic activity of the substance. Thus, by following the pharmacokinetic activity of the tracer, the pharmacokinetic activity of the substance may be determined. The tracer itself may be determined within a subject using any suitable method, depending on the tracer. As an example, the tracer may be determined by administering an indicator able to interact with the tracer. For instance, the indicator may be applied to the skin of the subject, and the indicator may give a different visual appearance based on the concentration of the tracer, or otherwise exhibit a determinable change in a property of the indicator. Other aspects of the invention are generally directed to methods of making or using tracers, methods of promoting the making or use of such tracers, kits involving such tracers, and the like. | 10-28-2010 |
20100310469 | VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and method for eliciting an immune response to endogenous or exogenous tumor antigens. | 12-09-2010 |
20100310470 | IMMUNOMODULATORY POLYMERIC ANTIGENS FOR TREATING INFLAMMATORY PATHOLOGIES - Provided are natural and synthetic immunomodulatory polymeric antigens (SPAs), compositions containing SPAs, and methods of using these natural and synthetic SPAs and compositions to prevent or treat inflammatory pathologies. | 12-09-2010 |
20110243856 | Permeable Mixtures, Methods and Compositions for the Skin - Topical mixtures with ranges of permeability which promote dermal healing, wound stage arrest, skin cooling, and patient comfort through pH adjustment, therapeutic ingredient carriage, water and oxygen delivery, with superior aesthetics and ease of cleaning features. | 10-06-2011 |
20110262365 | METHODS OF DIAGNOSING HYPERSENSITIVITY TO A FEMALE REPRODUCTIVE HORMONE AND TREATING MEDICAL CONDITIONS ASSOCIATED WITH SAME - Provided are methods of diagnosing a medical condition associated with hypersensitivity to a female reproductive hormone in a subject, with the proviso that the medical condition is not estrogen dermatitis. The method is effected by administering into a skin of the subject at least one female reproductive hormone such as estriol or estrone, and monitoring a reaction to the female reproductive hormone on the skin, wherein a presence of the reaction above a predetermined threshold is indicative of the presence of the medical condition in the subject. Also provided are methods and computing platforms for treating the medical conditions associated with the hypersensitivity to the female reproductive hormone by desensitization. | 10-27-2011 |
20120039814 | Topical Compositions and Methods of Detection and Treatment - A topical composition includes a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein. The hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point below the melting point of the respective hydrophobic material. The nanoemulsion further includes one or more pharmaceutically active agents and/or one or more chemiluminescent disease-detecting systems. | 02-16-2012 |
20120064011 | PREPARATION FOR EXTERNAL APPLICATION - Preparations for external application to human and animal skin, comprising: a) a composition in the form of a fluid nanophase system, comprising the components of a1) at least one water-insoluble substance with a water solubility of less than 4 gram per liter, a2) at least one amphiphilic substance (NP-MCA), which has no surfactant structure, does not build structures alone, the solubility of which is between 4 g and 1000 g per liter in water or oil and which does not enrich preferably at the oil-water interface, a3) at least one anionic, cationic, amphoteric and/or non-ionic surfactant, a4) at least one polar protic solvent, in particular having hydroxy functionality, a5) if necessary one or more adjuvants, wherein the percentage relate to the total weight of the composition each; and b) a therapeutic, cosmetic or diagnostically effective agent in a therapeutic, cosmetic or diagnostically effective amount. | 03-15-2012 |
20130034502 | Color Changing Cosmetic - The present invention is a substance that allows users to monitor temperature changes and appearance cosmetically on the human body by a change in color of the applied substance. It is intended for direct application to the skin and hair. The range of colors can be adjusted depending on the demand for the specific product or desired effect. The product is meant to be a temporary solution to cosmetically visually show the users temperature or change how the user looks. The cosmetic substance can be applied in many different ways and its unique color changing characteristics can be used on many products. | 02-07-2013 |
20130052139 | METHOD AND KIT FOR QUANTIFYING RISK PREDICTOR - A method and a kit for quantification of at least one predictor promoting at least one multifactorial disease, intended for use in assessment of the risk for developing or progression of the at least one multifactorial disease for a subject are disclosed. The kit comprises a plurality of reservoir units ( | 02-28-2013 |
20140023593 | IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. | 01-23-2014 |
20140241994 | Method and system for calculating a quantification indicator for quantifying a dermal reaction on the skin of a living being - This method is designed for calculating a quantification indicator for quantifying a dermal reaction on a skin having several chromophores. The method includes illumination of a zone to be characterized on the skin, the skin reaction being included in the zone to be characterized; and measurement of the spectrum of a back scattered radiation coming from the skin after illumination of said zone to be characterized. The method also includes determination, according to the measured spectrum, of an absorption coefficient value for the zone to be characterized, and calculation, according to the absorption coefficient value, of each chromophore concentration. The method includes calculation of the quantification indicator according to each calculated chromophore concentration. The method includes determination, according to the measured spectrum, of a diffusion coefficient value of the zone to be characterized, and the quantification indicator is further calculated according to the diffusion coefficient value. | 08-28-2014 |
424900810 | Visible immune reaction (e.g., allergy testing, etc.) | 27 |
20080199405 | Compounds and methods for immunotherapy and diagnosis of tuberculosis - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 08-21-2008 |
20080274059 | MITE FUSION PROTEINS - The present invention relates to fusion proteins comprising a Group I allergen and a Group II allergen from the genus | 11-06-2008 |
20090175798 | Mycobacterial Catalase-Peroxidase in the Diagnosis and Treatment of Sarcoidosis - Provided are diagnostic and therapeutic methods of treating sarcoidosis comprising the use of microbial catalase-peroxidase protein, its peptide fragments, or derivatives thereof. | 07-09-2009 |
20090202443 | METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs. | 08-13-2009 |
20090269285 | Diagnostic And Therapeutic Epitope, And Transgenic Plant - A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence | 10-29-2009 |
20090324503 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 12-31-2009 |
20100047182 | IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. | 02-25-2010 |
20100143262 | Method for Identifying Allergenic Proteins And Peptides - A method for identifying allergenic proteins and peptides. More specifically, a method for identifying allergenic milk proteins and/or peptides including the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding capacity as determined in step c) with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide of step d) at least one mediator. | 06-10-2010 |
20100278752 | Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission - The invention generally features methods for the prevention and detection of a tick infestation. The present invention also features methods for decreasing the ability of a tick to feed on a subject. | 11-04-2010 |
20100278753 | Device and Method for the Diagnosis of Gastrointestinal Allergy - A method and device for the diagnosis of gastrointestinal allergy. The method and the device expose a surface to at least one antigen at a fixed depth. The device includes an application point each having an antigen allowing for the application of the antigen to the surface at a fixed depth. The device may include multiple applications points each with an antigen for simultaneously applying the antigens to the surface. | 11-04-2010 |
20100310472 | DNA SEQUENCE, AND RECOMBINANT PREPARATION OF THE GRASS POLLEN ALLERGEN LOL P 4 - The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies. | 12-09-2010 |
20110135578 | MYCOBACTERIAL INFECTIONS - The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of | 06-09-2011 |
20110318274 | VARIANT OF MITE ALLERGEN AND USES THEREOF - The present invention relates to a new variant of the group 2 allergen from the house dust mite | 12-29-2011 |
20120014881 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 01-19-2012 |
20120087870 | NOVEL CAVIIDAE ALLERGENS AND USES THEREOF - The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3 (Cav p 6) or SEQ ID NO 19 ( | 04-12-2012 |
20120107247 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines - The present invention is directed to reagents useful for generating immune responses to | 05-03-2012 |
20120177581 | BYSTANDER IMMUNE SUPPRESSION AS A PREDICTOR FOR RESPONSE TO A VACCINE - The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented. | 07-12-2012 |
20130101523 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 04-25-2013 |
20130108553 | Metal Mixes For Use In Epicutaneous Patch Test | 05-02-2013 |
20130136699 | DIAGNOSTIC REAGENTS - There is provided a skin test diagnostic reagent comprising at least one CFP-10 epitope polypeptide, at least one ESAT-6 epitope polypeptide and at least one Rv3615c epitope polypeptide, the reagent eliciting a positive result when administered in a skin test to an animal infected with | 05-30-2013 |
20130183248 | METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA - Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria. | 07-18-2013 |
20130302254 | ANTIVENOM - The use of scorpion antivenom for the manufacture of a medicament for treatment of hypertension and/or cancer in a subject is disclosed as well as the treatment of the subject. | 11-14-2013 |
20140241995 | MICROPATCH FOR ASSESSING CHEMICAL CONTACT ALLERGY - The micropatch of the present invention provides a reliable and effective system of elicitation necessary for the diagnostic identification of allergy cases whilst substantially reducing the chances of sensitising subjects, the present invention employs a micropatch. | 08-28-2014 |
20140301953 | ALLERGENS FROM INSECTS - The invention relates to test kits for the determination of allergic dermatitis caused by insect bites in an animal such as horses, and to compositions and methods for desensitization. It was found that a culture supernatant or a cell extract of Sf21 insect cells is suitable for reliable test kits and for compositions for desensitization. | 10-09-2014 |
20150291669 | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof - Recombinant | 10-15-2015 |
20160103127 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8 | 04-14-2016 |
20160106723 | METHODS TO SENSE AND TREAT SUBCLINICAL SKIN DAMAGE - A method of sensing and removing subclinical, precancerous cells from skin wherein the unblemished skin is not being treated for AK, fine lines or clinical wrinkles and is not chronically exposed to sun or UV radiations, the method comprising topically applying to skin of a patient a composition essentially comprising of an TLR7 agonist agent, Imiquimod in an amount effective to induce a cellular immune response in the skin resulting in the sensing and removal of subclinical, atypical keratinocytes by erythema, scaling, crusting, or combinations thereof. | 04-21-2016 |